AGuIX

DRUG3 trials

Sponsors

University Hospital, Grenoble, Centre Leon Berard, Dana-Farber Cancer Institute

Conditions

Advanced Pancreatic AdenocarcinomaBrain MetastasesDuctal Adenocarcinoma of the PancreasNon-small Cell Lung CancerUnresectable Pancreatic Cancer

Phase 1

Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles

CompletedNCT02820454

University Hospital, GrenobleBrain Metastases

Start: 2016-03-31End: 2019-02-28Updated: 2019-06-07

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

RecruitingNCT04789486

Dana-Farber Cancer InstituteAdvanced Pancreatic Adenocarcinoma, Ductal Adenocarcinoma of the Pancreas, Non-small Cell Lung Cancer +1

Start: 2021-05-27End: 2027-09-10Target: 100Updated: 2025-05-23

Phase 2

Evaluating AGuIX® Nanoparticles in Combination With Stereotactic Radiation for Brain Metastases

TerminatedNCT04094077

Centre Leon BerardBrain Metastases

Start: 2020-01-17End: 2021-02-24Updated: 2021-06-08

Related Papers

NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution.

2024-07-319 citations

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)

BMC Cancer2023-04-1549 citations

Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol

BMJ Open2019-02-01131 citations